Metastatic prostate cancer is a type of cancer that began in the prostate gland and has spread to other areas of the body, ...

The American Urological Association recommends baseline PSA screening for average-risk men starting at age 45.

I am a healthy 89-year-old United States Army veteran. In August 2017, I was diagnosed with advanced prostate cancer and was ...

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

Hormone therapy for prostate cancer is aimed at reducing or eliminating the amount of testosterone in your body to slow or stop prostate cancer cells from growing and multiplying. Hormone therapy ...

Background: The costs of treating localized, Gleason score 9 and 10 prostate cancer remain poorly described, especially when the particularly aggressive nature of the disease often requires a ...

Patients with prostate cancer may have a lower risk of recurrence if they take multivitamin supplements after diagnosis, new data suggest.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The prostate cancer patients were on average 63 (±6.3) years old at diagnosis. For 242 (65%) patients, the PSA value at diagnosis was below 10 ng/ml; the clinical stage was classified as T1-T2a ...

Background: In this population-based study, we investigated the degree of concordance between Gleason scores obtained from prostate biopsies and those obtained from prostatectomy specimens, as ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...